Development and validation of the Adverse Inpatient Medication Event model (AIME). Issue 3 (5th November 2020)

• Record Type: Journal Article
• Authors: Falconer, Nazanin; Barras, Michael; Abdel‐Hafez, Ahmad; Radburn, Sam; Cottrell, Neil
• Is Part Of: British journal of clinical pharmacology. Volume 87:Issue 3(2021)
• Page Start: 1512
• Page End: 1524
• Publication Date: 2020-11-05
• Subjects: adverse drug events -- adverse drug reactions -- clinical pharmacology -- clinical pharmacy -- medication harm -- predictive risk model -- risk prediction; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14560
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: Medication harm has negative clinical and economic consequences, contributing to hospitalisation, morbidity and mortality. The incidence ranges from 4 to 14%, of which up to 50% of events may be preventable. A predictive model for identifying high‐risk inpatients can guide a timely and systematic approach to prioritisation. The aim of this study is to develop and internally validate a risk prediction model for prioritisation of hospitalised patients at risk of medication harm. Methods: A retrospective cohort study was conducted in general medical and geriatric specialties at an Australian hospital over six months. Medication harm was identified using International Classification of Disease (ICD‐10) codes and the hospital's incident database. Sixty‐eight variables, including medications and laboratory results, were extracted from the hospital's databases. Multivariable logistic regression was used to develop the final risk model. Performance was evaluated using area under the receiver operative characteristic curve (AuROC) and clinical utility was determined using decision curve analysis. Results: The study cohort included 1982 patients with median age 74 years, of which 136 (7%) experienced at least one adverse medication event(s). The model included: length of stay, hospital re‐admission within 12 months, venous or arterial thrombosis and/or embolism, ≥ 8 medications, serum sodium < 126 mmol/L, INR > 3, anti‐psychotic, antiarrhythmic and immunosuppressant medications, and history of medication allergy. Validation gave an AuROC of 0.70 (95% CI: 0.65–0.74). Decision curve analysis identified that the AIME may be clinically useful to help guide decision making in practice. Conclusion: We have developed a predictive model with reasonable performance. Future steps include external validation and impact evaluation.